Search company, investor...

MEDI Futures


Series C | Alive

Total Raised


Last Raised

$5.24M | 2 yrs ago

About MEDI Futures

MEDI Futures is a biomedical company developing ultrasonic endoscopic disk surgical instruments and enzyme-free ultrasound stem cell separators based on ultrasonic platform technology. The company has developed and exported medical sutures with strong, high-precision anchoring points (barbed sutures).

Headquarters Location


South Korea

+82 2-2138-3112

Missing: MEDI Futures's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MEDI Futures's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MEDI Futures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MEDI Futures is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

MEDI Futures Patents

MEDI Futures has filed 7 patents.

The 3 most popular patent topics include:

  • Arteries of the head and neck
  • Graphical projections
  • Honeycombs (geometry)
patents chart

Application Date

Grant Date


Related Topics




Woven fabrics, Synthetic fibers, Barbs (fish), Technical fabrics, Textiles


Application Date


Grant Date



Related Topics

Woven fabrics, Synthetic fibers, Barbs (fish), Technical fabrics, Textiles



Latest MEDI Futures News

19:54 ET MEDI FUTURES achieves $10.6M in total investments for its highly-recognized, original ultrasound medical device technol...

Aug 12, 2021

News provided by Share this article Share this article SEOUL, South Korea, Aug. 11, 2021 /PRNewswire/ --  MEDI FUTURES , a company known for the development of ultrasound medical platforms and a member of  Born2Global Centre , has officially made the list of companies that have attracted more than USD 10 million in investments. Recently, the company attracted USD 5.2 million in common stock investments from  DS Asset Management , helping it surpass the USD 10 million investment mark with an accumulated total of USD 10.6 million in investments. Team MEDI FUTURES MEDI FUTURES recorded annual sales of USD 1.7 million in 2020, just five years after its founding in 2016. 1 private equity asset management company and is operated by Chairman Deok-soo Jang, who is famous for his OTC stock market expertise. The asset company currently manages more than USD 1.4 billion in total assets and has recently been expanding its investments in innovative industries. Seong-wook Na, Head of DS Asset Management, commented on the investment saying, "MEDI FUTURES is a highly profitable company with differentiated technologies and products. It is also a company with high potential for global market expansion through global partnerships." He added, "We will continue to cooperate with MEDI FUTURES and support the company's growth." MEDI FUTURES is now researching biomaterials, including stem cells, and developing ultrasonic surgical instruments based on its own original ultrasound technology. The company's commercialized technology for separating adipose-derived stem cells using enzyme-free ultrasound enables medical practitioners to utilize biomaterials that are harmless to the human body—without the side effects typically associated with chemical enzymes—for a variety of purposes, including reconstructive surgery. MEDI FUTURES is also conducting R&D on technology-based human organ regeneration and skin and tissue reconstruction. Ji-min Kim, CEO of MEDI FUTURES, said, "Using this investment, we will continue to grow as a company that pursues two values: health and happiness." He added, "We will continue to meaningfully expand our business to realize our values of curing disease, improving people's health, and ensuring the universal happiness of more people." For more detailed information on MEDI FUTURES, visit . Media contact

MEDI Futures Frequently Asked Questions (FAQ)

  • Where is MEDI Futures's headquarters?

    MEDI Futures's headquarters is located at Seoul.

  • What is MEDI Futures's latest funding round?

    MEDI Futures's latest funding round is Series C.

  • How much did MEDI Futures raise?

    MEDI Futures raised a total of $11.65M.

  • Who are the investors of MEDI Futures?

    Investors of MEDI Futures include DS Asset Management, JB Investment, ST Capital, Samho Green Investment and The Wells Investment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.